These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25497227)

  • 1. Current treatment strategies for inhibiting mTOR in cancer.
    Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
    Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
    Myers AP
    Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
    Lv X; Ma X; Hu Y
    Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3 kinase in cancer.
    Bauer TM; Patel MR; Infante JR
    Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
    Diaz-Padilla I; Duran I; Clarke BA; Oza AM
    Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
    Zask A; Verheijen JC; Richard DJ
    Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
    Gomez-Pinillos A; Ferrari AC
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-competitive inhibitors of mTOR: an update.
    Schenone S; Brullo C; Musumeci F; Radi M; Botta M
    Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
    Khokhar NZ; Altman JK; Platanias LC
    Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors in cancer therapy.
    Zaytseva YY; Valentino JD; Gulhati P; Evers BM
    Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.